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ACS = acute coronary syndrome 38 
AMI = acute myocardial infarction 39 
DAPT = dual antiplatelet therapy 40 
DES = drug eluting stent 41 
GP = glycoprotein 42 
HTPR = high on-treatment platelet reactivity 43 
MACE = major adverse cardiovascular events 44 
PPCI = primary percutaneous coronary intervention 45 
PCI = percutaneous coronary intervention 46 
STEMI = ST-segment elevation myocardial infarction  47 
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Abstract 48 
Platelet activation and aggregation have a pivotal role in arterial thrombosis and in the 49 
pathogenesis of both acute coronary syndromes (ACS) and in the thrombotic complications 50 
that occur in patients undergoing percutaneous coronary intervention (PCI). The last 30 years 51 
has seen the progress from early trials of clopidogrel and glycoprotein IIb/IIIa inhibitors, to 52 
the application of more potent P2Y12 inhibitors prasugrel and ticagrelor. Early enthusiasm for 53 
newer and more potent antiplatelet agents, which could reduce ischaemic events, has led to 54 
the understanding of the importance of bleeding and a desire to individualise and optimise 55 
treatment. It has increasingly become apparent that the potency and duration of dual 56 
antiplatelet therapy (DAPT) has to reflect the balance between ischaemic and bleeding risk. 57 
Recently, multiple strategies have been proposed to individualise DAPT intensity and 58 
duration, in order to reduce the bleeding and ischaemic risks. Strategies of de-escalation of 59 
DAPT intensity, as well as shorter (less than a year) or more prolonged (beyond a year) 60 
treatment have been proposed, as well as platelet function test and genotype guidance of 61 
P2Y12 inhibitor therapy. Herein, we provide an overview of the progress in the field of 62 
antiplatelet therapy for ACS and PCI over the years, showing the current directions of travel. 63 
Ongoing studies focusing on personalised antiplatelet treatment will hopefully yield further 64 
insight into ways of optimising outcomes for the individual.  65 
Word count: 225  66 
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Importance of platelets in ACS and post-PCI complications 67 
Platelet activation and aggregation have a pivotal role in arterial thrombosis and in the 68 
pathogenesis of both acute coronary syndromes (ACS) and in the thrombotic complications 69 
that occur in patients undergoing percutaneous coronary intervention (PCI). In the 1980s, 70 
post-mortem studies showed that in the majority of patients who died from sudden death due 71 
to ischaemic heart disease, plaque disruption with overlying thrombus formation was 72 
responsible for the fatal acute myocardial infarction(AMI).(1,2) In most cases, the 73 
presentation of an ACS is attributable to acute changes in a coronary atheroma, with resultant 74 
platelet thrombus formation, which can result in downstream macro- or micro-infarction. 75 
Furthermore, thrombi are frequently observed at sites other than those of the major culprit 76 
lesion in patients with ACS.(1) The appreciation that thrombi in patients with ACS are 77 
predominantly formed of platelets(2) led to an increased search for antiplatelet therapy to 78 
treat and prevent coronary thrombosis.  79 
Balancing the risk of thrombosis against the risk of bleeding 80 
Antiplatelet therapy, while reducing thrombosis, also increases bleeding risk. For patients 81 
with ACS, there is a strong relationship between bleeding, mortality and AMI. Major 82 
bleeding significantly increases the risk of death(3,4) and AMI.(4) Bleeding often leads to 83 
attenuation or cessation of antithrombotic therapy, thus enhancing the thrombotic risk. 84 
Since both thrombotic and bleeding risks vary from one individual to the next, the benefits 85 
and risks of DAPT should be considered when deciding on the intensity and duration of 86 
DAPT. There is often a fine balance between benefit and risk, such that decisions on 87 
antiplatelet strategy should incorporate an assessment of both ischaemic and bleeding risks, 88 
with respect to both the intensity and the duration of DAPT. Risk scores can be helpful to 89 
guide DAPT treatment, and include the DAPT,(5) the PRECISE-DAPT (PREdicting bleeding 90 
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Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet 91 
Therapy) ,(6)  and the PARIS (Patterns of non-Adherence to Anti-Platelet Regimen in Stented 92 
Patients) scores.(7) However, their use is somewhat limited, and prospective trials have not 93 
validated the safety of using these scores to guide DAPT duration. In addition, there is a large 94 
overlap between bleeding and thrombotic risk factors in traditional scores, thus preventing a 95 
reasonable evaluation of the net benefit. More recently, the Academic Research Consortium 96 
for High Bleeding Risk (ARC-HBR) has proposed a new definition of high bleeding risk to 97 
provide consistency in clinical trials evaluating the safety and effectiveness of devices and 98 
drug regimens for patients undergoing PCI, defined as ≥4% risk of Bleeding Academic 99 
Research Consortium (BARC) 3-5 bleeding or a ≥1% risk of intracranial haemorrhage at 1 100 
year.(8)  101 
 102 
Early antithrombotic therapy 103 
In 1988, the landmark Second International Study of Infarct Survival (ISIS-2) trial in 17,187 104 
patients with suspected AMI showed unequivocally that for every 1000 patients, treatment 105 
with aspirin led to a reduction of about 25 deaths and 10-15 non-fatal reinfarctions or strokes 106 
during the first month and that the benefits of early treatment with aspirin were largely 107 
independent of, and additive to, those of fibrinolytic therapy (Table 1).(9) The 108 
Antithrombotic Trialists’ Collaboration meta-analysis involving 287 studies established that 109 
antiplatelet therapy, primarily with aspirin, reduces the incidence of death, AMI or stroke in 110 
patients at high vascular risk by 25%.(10) Aspirin became first-line therapy for all patients 111 
with cardiovascular disease, including ACS and those undergoing PCI, and remains so in 112 
current guidelines.(11,12) The mechanism of action of aspirin and other antiplatelet 113 
medications is shown in Figure 1. 114 
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P2Y12 inhibitors 115 
 116 
The CURE trial in 2001, showed that the addition of clopidogrel to aspirin in patients with 117 
ACS reduced major adverse cardiovascular events (MACE) by 20% compared to aspirin 118 
alone in patients suffering from non-ST-elevation ACS (Table 1 and Figure 2).(13) 119 
Subsequent studies showed that dual antiplatelet therapy (DAPT) comprising of clopidogrel 120 
and aspirin reduced MACE after PCI in both stable angina and ACS patients when compared 121 
with aspirin alone.(14) 122 
The antiplatelet effect of clopidogrel is relatively modest, however, taking up to 8 hours to 123 
achieve maximal effect and did not fully eliminate the recurrent ischaemic events post-AMI. 124 
Subsequent generations of P2Y12 receptor inhibitors prasugrel (a third-generation 125 
thienopyridine) and ticagrelor (a non-thienopyridine P2Y12 -inhibitor) both achieve more 126 
rapid and significantly higher levels of platelet inhibition compared with clopidogrel.(15,16) 127 
Subsequently, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing 128 
Platelet Inhibition with Prasugrel – Thrombolysis in Myocardial Infarction (TRITON-TIMI) 129 
38 and the study of Platelet Inhibition and Patient Outcomes (PLATO) studies demonstrated 130 
that prasugrel and ticagrelor, respectively, were superior to clopidogrel in terms of reducing 131 
ischaemic events, albeit with a higher risk of bleeding.(15–17) Subsequent studies, including 132 
a sub-group analysis of patients from the PLATO trial who were treated with primary PCI 133 
(PPCI) revealed that stent thrombosis occurred significantly less often in ticagrelor- than in 134 
clopidogrel-treated patients(18) demonstrating the importance of platelet inhibition in also 135 
preventing  stent thrombosis. Prasugrel and ticagrelor have therefore become first line 136 
treatment in ACS,(11,12) and for many years have been used largely interchangeably 137 
assuming similar effectiveness in the absence of head-to-head trials. A very recent head-to-138 
head comparison of prasugrel and ticagrelor in the ISAR-REACT 5 study, demonstrated that 139 
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in patients with ACS, treatment with prasugrel significantly reduced the risk of the composite 140 
of death, myocardial infarction or stroke compared to ticagrelor, without an increase in major 141 
bleeding.(19) This highlights the risks associated with assuming similar efficacy of 142 
treatments based on pharmacodynamic data and trials of individual drugs in similar patient 143 
cohorts, that may be misleading in the absence of direct comparison, which is essential to 144 
determine the true comparative effectiveness of medications. 145 
 146 
Glycoprotein IIb/IIIa inhibitors 147 
 148 
The final common pathway of platelet aggregation involves the binding of fibrinogen to 149 
adjacent platelets by means of glycoprotein IIb/IIIa integrin on the platelet surface. The role 150 
of suboptimal platelet inhibition at the time of PCI as a contributor to early stent thrombosis 151 
post-PCI is well recognised. Potent intravenous glycoprotein IIb/IIIa inhibitors (GPI) 152 
abciximab, tirofiban, and eptifibatide have all been shown to reduce the incidence of death 153 
and recurrent AMI in high-risk patients undergoing PCI compared with unfractionated 154 
heparin alone, particularly in the setting the ACS.(20–22) Importantly, this reduction in 155 
events was mainly driven by a reduction in periprocedural myocardial infarction. 156 
A large-scale meta-analysis of 221,066 patients with 4,276 episodes of stent thrombosis, 157 
reported that early DAPT discontinuation was one of the most important predictors of stent 158 
thrombosis.(23) The role of potent platelet inhibition in reducing stent thrombosis is further 159 
supported by the observation that GPI treatment in ACS reduces acute stent thrombosis 160 
compared with heparin alone.(24,25) Although met with initial enthusiasm, GPI significantly 161 
increased the risk of bleeding, and have not been shown to have net clinical benefit in low-162 
risk ACS or stable coronary disease patients. The appreciation of the risk of bleeding 163 
© 2020 Thieme Publishing Group. This is an accepted manuscript of an article accepted for pubication in Thrombosis and haemostasis
 8 
impacting on mortality has led to a significant reduction in GPI use but these drugs continue 164 
to have a role in high-risk ACS patients undergoing PCI. 165 
 166 
Importance of high on treatment platelet reactivity 167 
 168 
The desire to avoid recurrent ischaemic events which occurred in some patients despite 169 
DAPT, led to studies to try and identify “non-responders” to clopidogrel.(26,27) In ACS 170 
patients treated with PCI and DAPT including clopidogrel, persistent high on-treatment 171 
platelet reactivity (HTPR) to adenosine diphosphate was shown to be associated with a 172 
significant increase in non-fatal myocardial infarction, stent thrombosis, and cardiovascular 173 
mortality.(28–34)  174 
Furthermore, 20-30% of patients with ACS show an inadequate response to clopidogrel, 175 
depending on the platelet function test used.(35) Some 5-12% of the variation of adenosine 176 
diphosphate-induced platelet aggregation is related to genetic polymorphisms encoding 177 
CYP2C19, the hepatic enzyme responsible for biotransformation of clopidogrel to its active 178 
metabolite.(36) The CYP2C19 618G>A*2 allele, carried by about 30% of Caucasians and 179 
50% of East Asians,(35) is the most common polymorphism, resulting in loss of function 180 
(LoF) of CYP2C19 enzyme activity. Homozygotes for the CYP2C19*2 and less common 181 
CYP2C19*3 LoF alleles are poor metabolizers, and heterozygotes are intermediate 182 
metabolizers of clopidogrel. These individuals have high-on clopidogrel platelet reactivity 183 
and an increased risk of adverse cardiovascular events, including an increased risk of AMI 184 
and stent thrombosis, particularly post-PCI.(37) In the FAST-MI registry, amongst 2208 185 
patients receiving clopidogrel, those carrying two CYP2C19 LoF alleles (*2, *3, *4, or *5), 186 
experienced a two-fold increase in cardiovascular events compared to those without LoF 187 
alleles, an effect most marked amongst those undergoing PCI.(38) In a meta-analysis 188 
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involving 9,685 patients (91% undergoing PCI and 55% with ACS), those carrying one or 189 
two CYP2C19*2 alleles had increased rates of cardiovascular events compared with non-190 
carriers and an increased risk of stent thrombosis.(39) Consequently, in 2010, the US Food 191 
and Drug Administration announced a boxed warning on clopidogrel stating that the drug has 192 
a reduced effect in patients based on their CYP2C19 genotype. A meta-analysis assessing 32 193 
studies involving 42,016 patients concluded that although there was an association between 194 
the CYP2C19 genotype and clopidogrel responsiveness, there was no significant association 195 
of genotype with cardiovascular events.(40) However, a subsequent meta-analysis showed 196 
that the association of CYP2C19 genotype with adverse cardiovascular outcomes in whites 197 
was restricted to those undergoing PCI, and conferred a greater risk in Asians undergoing 198 
PCI.(41) By contrast, the CYP2C19*17 gain-of-function allele appears to confer enhanced 199 
response to clopidogrel and increased bleeding risk.(40,42) 200 
 201 
Individualised antiplatelet therapy 202 
Prasugrel and ticagrelor are not affected by CYP polymorphisms and these agents can 203 
eliminate the HTPR seen with clopidogrel in CYP2C19*2 allele carriers.(43,44) There is no 204 
evidence that escalating antiplatelet therapy based on CYP2C19 genotyping results in an 205 
improvement in clinical outcome and reduction in cardiovascular events. However, the very 206 
recently published POPular GENETICS study showed that in patients with STEMI 207 
undergoing PPCI, a genotype-guided de-escalation from prasugrel/ticagrelor to clopidogrel in 208 
those who are not CYP2C19*2 or 3* allele carriers results in a reduction in bleeding without 209 
an increase in thrombosis risk.(45)  210 
Studies were also conducted to assess the impact of overcoming HTPR on cardiovascular 211 
outcomes. In patients undergoing elective PCI with HTPR on clopidogrel, doubling the dose 212 
of clopidogrel in the Gauging Responsiveness With A VerifyNowTMAssay-Impact On 213 
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Thrombosis And Safety (GRAVITAS) trial(46) or switching from clopidogrel to prasugrel in 214 
the Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on 215 
Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) trial(47) failed to 216 
translate into an improvement in clinical outcome. Amongst patients undergoing PCI for 217 
stable coronary artery disease or non-ST elevation ACS, intensification of antiplatelet therapy 218 
based on the results of the VerifyNow assay by increasing the dose of aspirin, clopidogrel, or 219 
switching to prasugrel, or by additional treatment with GPI in the ARCTIC trial,(48) or using 220 
prasugrel or clopidogrel in elderly patients with ACS in the ANTARCTIC trial(49) failed to 221 
reduce the occurrence of adverse cardiovascular events. Thus, we now know that increasing 222 
the dose of clopidogrel or using more potent antiplatelet medications can reduce platelet 223 
reactivity and overcome HTPR on clopidogrel, but that this does not translate into an 224 
improvement in clinical outcomes in low-medium risk patients.(27,50)  225 
However, it is possible that these neutral results may be explained by trial designs that could 226 
not have shown the effectiveness of platelet function-guided P2Y12 inhibitor intensification. 227 
The GRAVITAS and the TRIGGER PCI trials enrolled low-risk patients in whom the 228 
observed MACE rate was so small, that a difference in outcome could not be detected given 229 
the relative sample size, whilst in the ANTARCTIC trial of higher risk elderly ACS patients, 230 
intensification of P2Y12 inhibitor treatment was only applied to 4% of patients. 231 
Furthermore, regardless of genotyping or testing for platelet reactivity, the use of ticagrelor or 232 
prasugrel is recommended over the use clopidogrel in patients with ACS.(11,12) 233 
Whether assessment of platelet reactivity or genotyping should be performed, remains 234 
unclear. Assessment of on-treatment platelet reactivity may be useful to identify high-risk 235 
individuals, but does not lead to useful information in terms of altering treatments and cannot 236 
be recommended in routine clinical practice. Benefits of genotyping include (i) the ability to 237 
use clopidogrel without fear of a higher risk of acute ischaemic events, esp. stent thrombosis, 238 
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in patients who carry two loss-of-function alleles, and potentially more widespread 239 
clopidogrel prescribing, which could lead to (ii) reduced bleeding complications in these 240 
patients compared with the use of newer P2Y12 inhibitors, and (iii) reduced prescribing costs, 241 
since clopidogrel is cheaper than the newer P2Y12 inhibitors. However, the negative aspects 242 
of routine screening include the fact that (i) the majority of ACS patients are now treated with 243 
prasugrel and ticagrelor because of their greater efficacy in reducing ischaemic events, (ii) 244 
genotyping is costly, (iii) there are logistic difficulties with implementing genotyping in a 245 
timely manner e.g. point-of-care testing, (iv) a large number of patients would have to be 246 
screened to identify a relatively small cohort who would benefit and (v) the cost-savings 247 
associated with cheaper prescribing costs of clopidogrel, in comparison to newer P2Y12 248 
inhibitors, would almost certainly be offset by the costs of genotyping (both testing costs and 249 
manpower). 250 
 251 
Speed and intensity of platelet inhibition 252 
 253 
The speed of onset and intensity of platelet inhibition during PCI is an important determinant 254 
of PCI-related ischaemic complications, and this is particularly relevant in ACS, especially 255 
ST-elevation myocardial infarction (STEMI).(33,51) However, the onset of action of oral 256 
P2Y12 receptor inhibitors is attenuated in STEMI patients, due to delayed absorption.(51) 257 
Crushing P2Y12 inhibitor tablets has been shown to provide more rapid platelet inhibition 258 
than standard oral dosing. Chewed ticagrelor tablets may also result in a similar effect.  259 
The intravenous P2Y12 inhibitor cangrelor has almost immediate onset of effect, is rapidly 260 
reversible and could provide the “bridging” antiplatelet effect required before the onset of 261 
effect of oral P2Y12 inhibitors. In the CHAMPION PHOENIX trial(52) in 11,145 patients 262 
undergoing PCI for the spectrum of coronary disease presentations (STEMI, non-ST-segment 263 
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elevation ACS, or stable angina) randomised to cangrelor or placebo, in addition to DAPT 264 
(aspirin and clopidogrel), showed that cangrelor significantly reduced the rate of ischaemic 265 
events, including stent thrombosis, during PCI, without significant increase in severe 266 
bleeding. This may be particularly relevant in patients with cardiogenic shock which is 267 
associated with delayed absorption of orally-administered P2Y12 inhibitors(53) 268 
  269 
Opioid and oral P2Y12 inhibitor interaction 270 
 271 
In the last few years, concerns have arisen about a possible negative pharmacodynamic 272 
interaction between opiates such as morphine and fentanyl, used for the relief of chest pain in 273 
AMI, and oral P2Y12 inhibitors.(54–57) A number of studies have shown that opioids delay 274 
the onset of effect and reduce the maximal platelet inhibition achieved by oral P2Y12 275 
inhibitors(54,58–60) through delay in gastrointestinal absorption.(61) In patients with stable 276 
coronary disease, morphine but not saline, was shown to significantly delay prasugrel 277 
absorption and the onset of platelet inhibition.(62) However, the clinical sequalae of this 278 
pharmacodynamic interaction is less clear, with no available prospective randomised trials 279 
assessing the impact of opioids in ACS on hard clinical endpoints. Small observational 280 
studies show varying impact on adverse cardiovascular events such as death and 281 
reinfarction(63–65) with a signal for increased events and larger infarct size with opiate-282 
use.(66) An observational study in patients with anterior STEMI showed a trend towards 283 
higher reinfarction rate in patients receiving morphine compared to those not receiving 284 
morphine,(67) whilst in the ATLANTIC-Morphine study, STEMI patients treated with 285 
ticagrelor and concomitant morphine had reduced pre-PPCI epicardial flow, were more 286 
frequently given GPI and more frequently underwent thrombus aspiration, indicating larger 287 
thrombus burden, than patients not receiving morphine.(68) A recent meta-analysis indicates 288 
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that STEMI patients treated with morphine may have a higher rate of early reinfarction 289 
compared to those treated without morphine.(69) The European Society of Cardiology 290 
downgraded the level of evidence for the use of intravenous opioids in the setting of STEMI 291 
from level I to level IIa.(11)  292 
Options to overcome the opioid-P2Y12 inhibitor interaction include the use of non-opioid 293 
analgesics such as intravenous paracetamol. If opioids are used, co-administration of 294 
metoclopramide can enhance ticagrelor absorption and platelet inhibition compared to 295 
morphine treatment alone.(70) Oral P2Y12 inhibitor absorption can also be improved by 296 
giving crushed ticagrelor or prasugrel through a nasogastric tube,(71–73) or using 297 
orodispersible ticagrelor.(70) Concomitant platelet inhibition can be achieved until oral 298 
medications can reach maximal effect, through the use of cangrelor,(74,75) or GPI(74,75).  299 
 300 
 301 
More intensive or prolonged antiplatelet therapy 302 
 303 
Following concerns of late stent thrombosis associated with drug-eluting stent (DES) 304 
implantation in the late 2000’s, prolonged DAPT treatment became recommended following 305 
PCI with DES for a minimum of 12 months. In current clinical practice, the default strategy 306 
in most centres is 12 months' DAPT followed by aspirin for life. The effect of more 307 
prolonged DAPT, beyond one year, in patients with ACS was assessed in the PEGASUS 308 
TIMI 54 study.(76) In 21,162 patients with prior AMI randomised to ticagrelor 90 mg twice 309 
daily, 60 mg twice daily, or placebo, in addition to aspirin, the use of ticagrelor 60 mg twice 310 
daily significantly reduced the occurrence of the composite of cardiovascular death, AMI, or 311 
stroke compared to placebo, at the expense of increased major bleeding.(76) More recently, 312 
the GLOBAL LEADERS study showed that DAPT for 1 month followed by ticagrelor 313 
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monotherapy for 23 months was not superior to 12 months of DAPT followed by 12 months 314 
of aspirin monotherapy with regards to mortality, ischaemic or bleeding complications.(77)  315 
 316 
Less intensive or shorter antiplatelet therapy 317 
 318 
The observation that ticagrelor and prasugrel significantly reduce ischaemic events but 319 
increase bleeding risk in ACS patients undergoing PCI, led to studies to assess shortened or 320 
less intensive DAPT regimens in order to achieve sufficient platelet inhibition with an 321 
acceptable bleeding risk.  322 
Following DES implantation, a number of studies have assessed the shorter DAPT regimens 323 
(≤3 months) and showed these to be noninferior to the traditional 12-month regimen with 324 
regard to the occurrence of ischaemic events.(78–81) A very recent systematic review and 325 
network meta-analysis, including 17 studies and 46,864 patients, concluded that compared 326 
with short term DAPT using clopidogrel, long term DAPT led to higher rates of major 327 
bleeding and non-cardiac death, and conventional term DAPT was associated with an 328 
increased risk of any bleeding. For patients with ACS, short term DAPT was shown to have 329 
similar efficacy and safety as standard term DAPT.(82)  330 
The effect of reducing the intensity of antiplatelet medication in ACS patients undergoing 331 
PCI was also assessed. The TOPIC trial of 646 patients with ACS evaluated the clinical 332 
benefit of unguided DAPT de-escalation by switching from prasugrel or ticagrelor to 333 
clopidogrel one month after PCI for ACS.  The primary end point of cardiovascular death, 334 
urgent revascularization, stroke and bleeding occurred half as often in the switched group as 335 
in the unswitched group, with the benefit driven by a reduction in bleeding events.(83) The 336 
TROPICAL-ACS trial in 2,610 patients with ACS undergoing PCI, showed that platelet 337 
function test-guided early de-escalation of antiplatelet therapy was non-inferior to standard 338 
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prasugrel therapy with similar rates of ischaemic events including cardiovascular death, AMI 339 
or stroke and a trend towards less bleeding during guided treatment.(84) However, in a pre-340 
specified sub-analysis according to diabetic status showed that de-escalation in patients with 341 
diabetes was associated with non-significant but numerically higher rate of the net clinical 342 
endpoint (composite of cardiovascular death, myocardial infarction, stroke or BARC ≥2 343 
bleeding) than standard of care, with no observed reduction in bleeding.(85) In a small sub-344 
study of TROPICAL-ACS,(86) in which 603 patients were genotyped 345 
for CYP2C19*2, *3 and *17 alleles, the CYP2C19*2 and CYP2C19*17 carrier status 346 
correlated with platelet reactivity in patients treated with clopidogrel but not, as expected, in 347 
those treated prasugrel, and was proposed as a way of identifying patients who may not be 348 
suitable for de-escalation of intensive antiplatelet treatment.(86) The ANTARCTIC trial in 349 
877 ACS patients ≥75 years showed similar ischaemic and bleeding rates with low dose 350 
prasugrel (5 mg/d), or with platelet function-guided prasugrel dose escalation (10 mg 351 
prasugrel) or de-escalation (75 mg clopidogrel).(49) Thus, in comparison to trials of platelet 352 
function-guided intensification of antiplatelet therapy whose results were largely neutral, 353 
trials of personalised de-escalation of P2Y12 inhibitor intensity appear to show promising 354 
results. In the STOP DAPT-2 trial, 3,045 patients undergoing PCI (38% with ACS) were 355 
randomized either to 1 month of DAPT followed by clopidogrel monotherapy or to 12 356 
months of DAPT with aspirin and clopidogrel.(87) Compared to patients receiving 12 months 357 
of DAPT, patients assigned to 1 month of DAPT had a significantly lower rate of the 358 
composite of cardiovascular death, AMI, ischaemic or haemorrhagic stroke, definite stent 359 
thrombosis, or major or minor bleeding at 12 months, meeting criteria for both noninferiority 360 
and superiority. The SMART-CHOICE trial(88) in which 2,993 patients undergoing PCI 361 
were randomised to aspirin plus a P2Y12 inhibitor for 3 months and thereafter P2Y12 inhibitor 362 
alone or DAPT for 12 months showed that P2Y12 inhibitor monotherapy after 3 months of 363 
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DAPT was non-inferior to prolonged DAPT with regards to major adverse cardiac and 364 
cerebrovascular events at 1 year. However, concerns have also emerged about shorter DAPT 365 
duration from the SMART-DATE non-inferiority trial conducted in South Korea, in which 366 
2712 patients with ACS undergoing PCI were randomised to 6-months or 12-month or longer 367 
open-label DAPT, predominantly with clopidogrel.(89) Whilst bleeding was similar in the 368 
two arms, the primary endpoint of the composite of all-cause death, myocardial infarction, or 369 
stroke at 18 months occurred more often in 6-month than in the 12-month or longer DAPT 370 
group (pnon-inferiority=0·03) driven by more frequent myocardial infarction, indicating that 371 
short-term DAPT may not be a safe option in these patients, particularly if clopidogrel is 372 
used.   373 
The recently published POPular AGE trial randomised patients aged 70 years or older to 374 
clopidogrel or prasugrel/ticagrelor, clopidogrel use was associated with significantly less 375 
bleeding without a signal for increase in ischaemic events.(90) 376 
The most recent publication in this area was the TWILIGHT study, in which more than 7000 377 
patients at high risk for bleeding or an ischemic event undergoing PCI were given 3 months 378 
DAPT with ticagrelor plus aspirin, and thereafter randomised to aspirin or placebo for 1 379 
year.(91) Compared to ongoing DAPT, ticagrelor monotherapy was associated with 380 
significantly lower occurrence of the primary end point of BARC type 2-5 bleeding. 381 
Although there was no observed increase in the risk of death, myocardial infarction, or stroke 382 
with monotherapy, the trial was underpowered to detect differences in the risk stent 383 
thrombosis and stroke.  384 
There is, therefore, significant momentum to now not only reduce ischaemic risk, but also 385 
bleeding risk in patients undergoing PCI, including for ACS, by reducing the intensity and 386 
duration of antiplatelet therapy where possible. However, it is important to note that most of 387 
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the studies assessing de-escalation were generally underpowered to reliably assess the safety 388 
of de-escalation on hard clinical endpoints, in particular myocardial infarction and stent 389 
thrombosis and the jury remains out regarding the safety of less intense or shorter duration of 390 
antiplatelet therapy for the majority of patients. It is possible that personalised therapy using 391 
genotyping or phenotyping with platelet function testing to assess the potential effectiveness 392 
of P2Y12 inhibitor treatment may allow de-escalation of antiplatelet therapy intensity to 393 
reduce bleeding, while avoiding ischaemic events. Apart from the logistic challenges of 394 
genotyping ACS patients in a timely manner, this concept is really only applicable to 395 
clopidogrel treatment, and assessment of platelet reactivity is more generalisable to all P2Y12 396 
inhibitors, including those currently in development (vide infra) and also more practicable. 397 
Furthermore, theoretically, effective platelet inhibition may negate the need for genotyping to 398 
assess drug effectiveness. Future large trials would be required to assess the safety and 399 
efficacy of such personalised approaches. 400 
 401 
Novel therapeutic targets  402 
Novel P2Y12 and P2Y1 inhibitors  403 
Novel P2Y12 inhibitors include selatogrel, AZD1283, and SAR216471 (Table 2).(92,93) 404 
Recently, in a phase 2 study, selatogrel was shown to provide rapid onset of potent, 405 
consistent platelet inhibition when given by subcutaneous injection.(93) In animal models, 406 
the platelet P2Y1 inhibitor BMS-884775 demonstrated similar efficacy to clopidogrel with 407 
less bleeding.(94) The combined P2Y12 and P2Y1 receptor antagonist GLS-409 appears to be 408 
a highly potent antithrombotic agent in an animal model, with minimal increase in bleeding 409 
time.(95)  410 
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Novel GP IIb/IIIa inhibitors 411 
Currently available GP IIb/IIIa inhibitors block all circulating platelets, and therefore 412 
significantly increase bleeding.  RUC-4, a novel small-molecule in development, is a potent 413 
antithrombotic agent which can be given by intramuscular injection, but its bleeding profile is 414 
unknown.(96) Conformation-specific targeting of GP IIb/IIIa, whereby only activated GP 415 
IIb/IIIa is inhibited, results in potent antithrombotic effects without increase in bleeding in 416 
pre-clinical models.(97) A novel approach targeting the GP IIb/IIIa integrin “outside-in” 417 
signalling, which normally triggers an intracellular signalling cascade resulting in granule 418 
secretion and clot retraction, has been shown, in animal models, to prevents occlusive 419 
thrombus formation without affecting haemostasis.(98) 420 
GPIb–vWF axis inhibitors 421 
The GP Ib–IX–V complex binds to vWF via its GP Ib subunit at sites of vascular injury and 422 
under conditions of high shear stress.  Although inhibitors of the GP Ib–vWF axis exhibit 423 
antithrombotic effects, development of two anti-vWF agents (an aptamer, ARC1779 and a 424 
single-domain antibody, caplacizumab) was halted due to bleeding concerns.(99,100) 425 
Anfibatide is a GP Ib antagonist that also inhibits vWF. Anfibatide has been shown to inhibit 426 
platelet adhesion and aggregation in a mouse model(101) and a phase II clinical trial in 427 
patients with STEMI is underway (http://www.clinicaltrials.gov. Unique identifier: 428 
NCT02495012).  429 
Phosphatidylinositol 3 Kinase B (PI3Kβ) inhibitors 430 
AZD6482 is an intravenous inhibitor of the lipid kinase PI3Kβ, important in signalling 431 
downstream of platelet receptors and mediating platelet adhesion under shear stress. In 432 
normal volunteers, AZD6482 exhibited mild antiplatelet effect but inhibited platelet 433 
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aggregation under shear-stress, with only mild prolongation of bleeding time, but with 434 
frequent epistaxis.(102) 435 
Protease-activated receptor (PAR) inhibitors 436 
Thrombin receptors PAR 1 and 4 mediate platelet activation and aggregation at low and high 437 
thrombin concentrations, respectively. PAR1 antagonists, such as vorapaxar, are potent 438 
antithrombotic agents, but significantly increase bleeding.(103) Parmodulins are a new class 439 
of PAR1 antagonists in development which exhibit antithrombotic effects in animal models 440 
without affecting haemostasis.(104) The PAR4 antagonist BMS-986120 has similar 441 
antithrombotic effects to clopidogrel, albeit with minimal effect on haemostasis(105) and in a 442 
phase 1 study was shown to provide selective and reversible PAR4 antagonism and platelet 443 
aggregation.(106) The PAR4 inhibitor BMS-986141 has been evaluated in a phase II clinical 444 
study for reduction of stroke recurrence (http://www. clinicaltrials.gov. Unique identifier: 445 
NCT02671461).  446 
Protein disulfide isomerase inhibitors  447 
Protein disulfide isomerase is required for thrombus formation, and inhibitors of this, such as 448 
isoquercetin, are being tested in phase II–III clinical trials of venous thrombosis in patients 449 
with cancer (http://www.clinicaltrials.gov. Unique identifier: NCT02195232).  450 
GP VI-collagen inhibitors 451 
Binding of the platelet GP VI receptor to collagen leads to the release of soluble agonists and 452 
activation of GP IIb/IIIa, resulting in platelet activation. A monoclonal antibody targeting the 453 
collagen-binding site of GP VI has, in pre-clinical studies, demonstrated antithrombotic 454 
effects without affecting haemostasis.(107) Another monoclonal antibody against GP VI has  455 
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recently been shown in a phase 1 study to achieve effective, dose-dependent inhibition of 456 
collagen-induced platelet aggregation without affecting haemostasis,(108) and a phase 2 trial 457 
is planned in stroke (NCT03803007). Revacept, another anti-GP VI agent, has also been 458 
shown to effectively inhibit collagen-induced aggregation without increase in bleeding(109) 459 
and is now being evaluated in phase 2 studies in coronary artery disease 460 
(http://www.clinicaltrials.gov. Unique identifiers: NCT03312855 a) and in symptomatic 461 
carotid stenosis (http:// www.clinicaltrials.gov. Unique identifier: NCT01645306).  462 
 463 
Conclusion 464 
There have been tremendous advances in antiplatelet therapy for ACS and PCI, particularly 465 
in the last 3 decades. The initial excitement about the development of newer and more potent 466 
antiplatelet agents, which could reduce ischaemic events, has led to an understanding of the 467 
importance of bleeding complications and given way to a desire to individualise and optimise 468 
treatment to also reduce bleeding risk. The future is also exciting. Ongoing studies focusing 469 
on personalising treatment, through the use of platelet function tests, genetic testing, and by 470 
prolonging and intensifying or by shortening or de-escalating antiplatelet therapy will 471 
hopefully yield further insight into ways of optimising antiplatelet therapy for the individual. 472 
Future antiplatelet therapy is likely to be more personalised, with a combination of 473 
individualised clinical risk assessment, incorporating perhaps both in vitro tests of thrombotic 474 
status as well as genomic studies may be necessary to provide the optimal patient profile to 475 
offer personalized antiplatelet therapy.  476 
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Figure Legends 896 
 897 
Figure 1. Mechanism of action of antiplatelet medications. 898 
Abbreviations: ADP = adenosine diphosphate, GP = glycoprotein, PAR = protease-activated 899 
receptor, TxA2 = thromboxane A2, VWF = von Willebrand factor 900 
 901 
Figure 2. Evolution of antiplatelet secondary prevention (aspirin plus P2Y12 inhibitor) trials 902 
in ACS and PCI.  903 
  904 




Table 1. Landmark trials of antiplatelet therapy in ACS and PCI. 907 
 908 
Table 2. New antiplatelet agents being evaluated in or beyond Phase 2 clinical trials. 909 
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